Food and Drug Administration (FDA) has issued a second approvable letter for bazedoxifene, a selective estrogen receptor modulator, for the prevention of postmenopausal osteoporosis.

苯卓昔芬是一种选择性雌体调节剂，为预防绝经后骨质疏松症药物。

Food and Drug Administration (FDA) has issued a second approvable letter for bazedoxifene, a selective estrogen receptor modulator, for the prevention of postmenopausal osteoporosis.

苯卓昔芬是一种选择性雌激素受体调，预防绝后骨质疏松症药物。

Food and Drug Administration (FDA) has issued a second approvable letter for bazedoxifene, a selective estrogen receptor modulator, for the prevention of postmenopausal osteoporosis.

苯卓昔芬是一种选择雌激素受体调节剂，为预防绝经后骨质疏松症药物。

Food and Drug Administration (FDA) has issued a second approvable letter for bazedoxifene, a selective estrogen receptor modulator, for the prevention of postmenopausal osteoporosis.

苯卓昔芬是一种选择性雌激素受体调节剂，绝经后骨质疏松症药物。

Food and Drug Administration (FDA) has issued a second approvable letter for bazedoxifene, a selective estrogen receptor modulator, for the prevention of postmenopausal osteoporosis.

苯卓昔芬是一种选择雌激素受体调节剂，为预防绝经后骨质疏松症药物。

Food and Drug Administration (FDA) has issued a second approvable letter for bazedoxifene, a selective estrogen receptor modulator, for the prevention of postmenopausal osteoporosis.

苯卓昔芬是一种选择性雌激素受体调节，防绝后骨质疏松症药物。

Food and Drug Administration (FDA) has issued a second approvable letter for bazedoxifene, a selective estrogen receptor modulator, for the prevention of postmenopausal osteoporosis.

苯卓昔芬是一种选择性受体调节剂，为预防绝经后骨质疏松症药物。

Food and Drug Administration (FDA) has issued a second approvable letter for bazedoxifene, a selective estrogen receptor modulator, for the prevention of postmenopausal osteoporosis.

苯卓昔芬是一种选择性雌激素受体调节剂，为预防绝质疏松症药物。

Food and Drug Administration (FDA) has issued a second approvable letter for bazedoxifene, a selective estrogen receptor modulator, for the prevention of postmenopausal osteoporosis.

苯卓昔芬是一种选激素受体调节剂，为预防绝经后骨质疏松症药物。